Soluble CD44 interacts with intermediate filament protein vimentin on endothelial cell surface

• Published in: PloS one 2011-12, Vol.6 (12), p.e29305-e29305
• Main Authors: Päll, Taavi, Pink, Anne, Kasak, Lagle, Turkina, Marina, Anderson, Wally, Valkna, Andres, Kogerman, Priit
• Format: Article
• Language: English
• Subjects: Alternative splicing; Amino acids; Angiogenesis; Animals; Binding sites; Biology; Breast cancer; Cancer; Cancer treatment; CD44 antigen; Cell adhesion; Cell adhesion & migration; Cell proliferation; Cell surface; Cells, Cultured; Clonal deletion; Collagen; Deletion mutant; Endocytosis; Endothelial cells; Endothelium; Endothelium, Vascular - cytology; Endothelium, Vascular - metabolism; Genes; Genomes; Glycoproteins; Humans; Hyaluronan Receptors - metabolism; Hyaluronic acid; Intermediate filament proteins; Ligands; Lungs; Lymphoma; Medical research; Medicine; Metastasis; Mice; Mice, Knockout; Mutants; Protein Binding; Proteins; Rodents; Serum levels; Shedding; Umbilical vein; Vimentin; Vimentin - genetics; Vimentin - metabolism; Xenografts
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0029305

CD44 is a cell surface glycoprotein that functions as hyaluronan receptor. Mouse and human serum contain substantial amounts of soluble CD44, generated either by shedding or alternative splicing. During inflammation and in cancer patients serum levels of soluble CD44 are significantly increased. Experimentally, soluble CD44 overexpression blocks cancer cell adhesion to HA. We have previously found that recombinant CD44 hyaluronan binding domain (CD44HABD) and its non-HA-binding mutant inhibited tumor xenograft growth, angiogenesis, and endothelial cell proliferation. These data suggested an additional target other than HA for CD44HABD. By using non-HA-binding CD44HABD Arg41Ala, Arg78Ser, and Tyr79Ser-triple mutant (CD443MUT) we have identified intermediate filament protein vimentin as a novel interaction partner of CD44. We found that vimentin is expressed on the cell surface of human umbilical vein endothelial cells (HUVEC). Endogenous CD44 and vimentin coprecipitate from HUVECs, and when overexpressed in vimentin-negative MCF-7 cells. By using deletion mutants, we found that CD44HABD and CD443MUT bind vimentin N-terminal head domain. CD443MUT binds vimentin in solution with a Kd in range of 12-37 nM, and immobilised vimentin with Kd of 74 nM. CD443MUT binds to HUVEC and recombinant vimentin displaces CD443MUT from its binding sites. CD44HABD and CD443MUT were internalized by wild-type endothelial cells, but not by lung endothelial cells isolated from vimentin knock-out mice. Together, these data suggest that vimentin provides a specific binding site for soluble CD44 on endothelial cells.